Transcriptome profiling of cell-free RNAs in prostate cancer patients on active surveillance
- 1Centre for Cancer Cell and Molecular Biology Barts Cancer Institute, Queen Mary University of London, London, UK
Abstract
Active surveillance (AS) delays or avoids unnecessary treatment-related side effects for early localised non-aggressive prostate cancer (PCa) through monitoring with regular prostate-specific antigen (PSA) testing, digital rectal examination (DRE), magnetic resonance imaging (MRI) and prostate biopsy. Whilst baseline MRI has prognostic value and is increasingly used for disease monitoring, molecular biomarkers could be an adjunct to refine risk stratification and disease prognostication [2]. Unlike tissue-based genomic classifiers such as Decipher (Veracyte) and Prolaris CCP (Myriad), blood-based molecular testing for example cell-free RNA (cfRNA) offers minimally invasive real-time monitoring. Moreover, cfRNA may yield genetic information shed from different cell populations within the tumour microenvironment, as well as the host circulation, expanding the opportunities for biomarker discovery. Here, we test the feasibility of whole transcriptome profiling of cfRNAs from the blood of PCa patients under AS, exploring differences between patients with stable disease (SD), and progression to radical prostatectomy (RP).
Related
- Baseline Patient and Tumour Characteristics Associated with Mental Health in Men Undergoing Active Surveillance for Prostate Cancer
- Personalized Boolean network dynamic profiling and machine learning approaches to identify combinatorial treatments for prostate cancer
- Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance
- Exercise During Active Surveillance for Localized Low-Risk Prostate Cancer: Current Evidence and a Survivorship Framework.
- From Radical Treatment to Structured Active Surveillance: A Narrative Review of Low-Risk Localized Prostate Cancer
BibTeX
@misc{foster2026transcriptome,
title = {{Transcriptome profiling of cell-free RNAs in prostate cancer patients on active surveillance}},
author = {J. G. Foster and E. Wozniak and C. A. Mein and J. Thompson and P. Stricker and A.-M. Haynes and P. Rajan},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.03.744568},
url = {https://www.biorxiv.org/content/10.64898/2026.09.03.744568v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Transcriptome profiling of cell-free RNAs in prostate cancer patients on active surveillance
AU - J. G. Foster
AU - E. Wozniak
AU - C. A. Mein
AU - J. Thompson
AU - P. Stricker
AU - A.-M. Haynes
AU - P. Rajan
PY - 2026
DA - 2026/09/03
PB - bioRxiv
DO - 10.64898/2026.09.03.744568
UR - https://www.biorxiv.org/content/10.64898/2026.09.03.744568v1
AB - Active surveillance (AS) delays or avoids unnecessary treatment-related side effects for early localised non-aggressive prostate cancer (PCa) through monitoring with regular prostate-specific antigen (PSA) testing, digital rectal examination (DRE), magnetic resonance imaging (MRI) and prostate biopsy. Whilst baseline MRI has prognostic value and is increasingly used for disease monitoring, molecular biomarkers could be an adjunct to refine risk stratification and disease prognostication [2]. Unlike tissue-based genomic classifiers such as Decipher (Veracyte) and Prolaris CCP (Myriad), blood-based molecular testing for example cell-free RNA (cfRNA) offers minimally invasive real-time monitoring. Moreover, cfRNA may yield genetic information shed from different cell populations within the tumour microenvironment, as well as the host circulation, expanding the opportunities for biomarker discovery. Here, we test the feasibility of whole transcriptome profiling of cfRNAs from the blood of PCa patients under AS, exploring differences between patients with stable disease (SD), and progression to radical prostatectomy (RP).
ER -